CATALYST PHARMACEUTICALS, INC. 4

Chief Commercial Officer Jeffrey Del Carmen disposed of all his Catalyst Pharmaceuticals equity (stock, options, and RSUs) for cash at the $31.50 per-share merger price in connection with the company’s acquisition by Angelini Pharma S.p.A.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief Commercial Officer Jeffrey Del Carmen had all of his equity awards cancelled and cashed out in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. at $31.50 per share. This included 14,337 shares of common stock disposed of at $31.50 per share (about $452,000) and multiple fully vested stock option grants covering an aggregate of 985,344 shares with exercise prices ranging from $3.42 to $22.77 per share, which were converted into cash equal to the intrinsic value of each option (total estimated option value of roughly $14.3 million at the $31.50 merger price). In addition, restricted stock units covering 51,502 shares of common stock were cancelled and similarly converted into cash based on the $31.50 per share merger consideration (about $1.6 million). Each option and RSU vested in full upon the merger’s consummation, and following these transactions Del Carmen no longer holds Catalyst equity, reflecting a change-of-control–driven liquidation of his equity position rather than open-market trading.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000174

Alert Tier

7